15 September 2010

Savient reiterates sale plans following approval of Krystexxa

Savient on Wednesday reiterated its plans to sell the company, just one day after the drugmaker received approval for its Krystexxa gout treatment. Shares in the company rose as much as 26 percent on the approval news.

Reference Articles
Savient’s shares surge after US approves new gout treatment - (Bloomberg)
Savient shares rally as FDA approves gout drug - (FinanzNachrichten)
Savient shares zoom 27% premarket on gout-drug OK - (MarketWatch)
Savient investors expect a sale - (

**Published in "First Word"

No comments:

Post a Comment

CONTACTO · Aviso Legal · Política de Privacidad · Política de Cookies

Copyright © Noticia de Salud